295P High dose rate (HDR) brachytherapy for prostate cancer in the early stages

High dose rate brachytherapy for prostate cancer.

High dose rate (HDR) afterloading brachytherapy in the management of localised prostate cancer has practical, physical and biological advantages over low dose rate seed brachytherapy. There are no free live sources used, no risk of source loss and since the implant is a temporary procedure following discharge no issues with regard to radioprotection use of existing facilities. Adequate coverage...

High-dose-rate Brachytherapy for Prostate Cancer

Introduction/Background Over the last 2 decades, significant technical advancements have improved the delivery of prostate brachytherapy. The transrectal ultrasound-guided implant technique is the backbone of modern prostate brachytherapy. Whether it is permanent or temporary, ie, low-dose-rate (LDR) or high-dose-rate (HDR), respectively, both use similar image-guided techniques for inserting s...

The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer

High-dose-rate (HDR) brachytherapy as monotherapy is a comparatively new brachytherapy procedure for prostate cancer. In addition to the intrinsic advantages of brachytherapy, including radiation dose concentration to the tumor and rapid dose fall-off at the surrounding normal tissue, HDR brachytherapy can yield a more homogeneous and conformal dose distribution through image-based decisions fo...

A Report on the Clinical Outcome after High-Dose Rate (HDR) Brachytherapy as Monotherapy in Early Prostate Cancer

BACKGROUND To report the clinical outcome after a single implant, high dose rate (HDR) brachytherapy in early prostate cancer. MATERIALS AND METHODS All clinically localized prostate cancer patients who underwent high-dose rate (HDR) brachytherapy as monotherapy (no external beam radiotherapy) from February 2006 to September 2011 were analyzed prospectively. Acute and chronic toxicity were as...

High-dose-rate Brachytherapy for Prostate